Huberman Lab Podcast Summary

Episode: Using Stem Cells to Cure Autism, Epilepsy & Schizophrenia
Guest: Dr. Sergiu Pașca
Host: Dr. Andrew Huberman
Release Date: August 18, 2025

Overview

This special episode features Dr. Sergiu Pașca—professor of psychiatry & behavioral sciences at Stanford—discussing advances in using stem cells, organoids, and assembloids to model, understand, and potentially cure profound autism, epilepsy, and schizophrenia. The conversation covers the spectrum and diagnosis of autism, the genetic and biological underpinnings of neurodevelopmental disorders, pioneering lab techniques, and both the ethical and therapeutic frontiers of neuroscience.

Dr. Pașca and Dr. Huberman explore not only the science but also the translational impact for real patients, the rise of stem cell tools in the clinic, and the importance of responsible communication in this rapidly evolving field.

Main Themes & Purposes

• Clarifying what autism is—and isn’t—and why the spectrum and variability matter for treatment goals.
• The genetics and biological mechanisms underpinning autism, including discussion of heritability, sex ratios, and diagnostic challenges.
• Cutting-edge lab models: how stem cells are used to build organoids ("mini-organs") and assembloids (assembled brain circuits) from patient cells with the aim of studying—and potentially curing—otherwise intractable brain disorders.
• The hope and hype of gene and stem cell therapies, with rigorous discussion of current realities, future directions, and ethical dilemmas.
• The importance of accurate language, collaborative science, and compassion for patients and families.

Key Topics & Insights

1. What Is Autism? Changes in Prevalence, Diagnosis & Understanding

• Autism as a spectrum:
  • Behaviorally-defined, can range from highly functional to profoundly impaired individuals. No singular biological marker exists.
  • "[Autism] is a spectrum, as you said... defined exclusively by observing behavior... which is actually the case for most psychiatric disorders." — Dr. Sergiu Pașca (03:03)
• Prevalence has risen:
  • Dr. Pașca: From a "rare disease" in his medical school days to almost 3% today (03:54).
  • Causes for the increase possibly include diagnostic criteria changes, migration between diagnostic categories (intellectual disability → autism), better awareness, and as yet unexplained other factors.
• Strong genetic component:
  • Twin studies: If one identical twin has autism, the other is highly likely to as well (04:38).
  • 20% of children diagnosed can now receive a specific genetic diagnosis—though actionable treatments may not (yet) exist (19:22).
• Sex ratio:
  • Diagnosed males outnumber females about 4:1, though this varies with severity and diagnostic methods. Possible resilience or symptom masking in females (07:31).
  • "Females preemies [premature infants] will do much better for whatever reasons, the way the nervous system is built..." — Dr. Pașca (08:10)

2. Genes, Environment, and the Elusive "Causes"

• Genetics:
  • Many genes implicated; categories include ion channel genes (channelopathies), synaptic proteins (synaptopathies), and chromatin/packaging genes (chromatinopathies) (17:38).
  • Some mutations are de novo (not present in parents).
  • Not all mutations guarantee severe disease (penetrance); phenotype can vary.
• Environment:
  • Some environmental factors, like thalidomide (now banned), increase risk, but overall genes dominate (24:08).
  • Other hypotheses (e.g., microbiome, vaccines) remain unproven.
    • "We cannot deny that perhaps improving the microbiome will improve...quality of life...But whether it's really causal, there's no clear evidence..." — Dr. Pașca (15:18)
    • "There's right now there are no published papers that...support the vaccine autism link." — Dr. Huberman (27:47)
• Complexity and uncertainty:
  • Autism is not just "one thing"—a parallel is drawn to 19th-century "fever" as a symptom caused by many diseases.
  • "[Psychiatric conditions] are defined behaviorally, but there is a disconnect with the biology." — Dr. Pașca (06:24)

3. Current State of Autism Treatment (and its Gaps)

• No single cure or treatment; behavioral therapy and supportive interventions are standard.
• Even with genetic diagnosis, families often lack targeted therapies.
• Treatments like fecal microbiota transplant and sleep/dietary interventions may impact symptoms, but lack proof of addressing underlying causes (15:18).
• Example: Timothy Syndrome—a rare, well-characterized genetic cause of profound autism—has inspired targeted drug development via stem-cell modeling (124:24).

4. Stem Cells: From Ethical Dilemma to Revolutionary Tool

a. The Problem with Early Stem Cells

• Early research relied on embryonic stem cells, raising major ethical concerns (45:04).

b. The Yamanaka Revolution (2006–2007)

• Induced Pluripotent Stem Cells (iPSC):
  • Shinya Yamanaka discovers that four genes, highly expressed in pluripotent cells, can reprogram adult skin cells to become pluripotent stem cells (46:00).
  • "Put those genetic factors in, turn those cells into pluripotent stem cells that we'd later on learn they're almost identical to those embryonic stem cells." — Dr. Pașca (47:34)
  • This technology circumvents the need for embryonic tissue, removing ethical barriers and allowing unlimited personalized stem cell lines.

c. Organoids & Assembloids: Building Brains in a Dish

• Organoids:
  • Self-organizing 3D cultures of neurons (and other cells) that recapitulate early brain development.
  • Can be kept alive and maturing for years, mirroring developmental timing—including the remarkable finding that "intrinsic timers" control their maturation state (70:18).
  • "Suddenly you could...recreate some of the circuits of the brain outside the body, without doing any harm." — Dr. Pașca (48:35)
• Assembloids:
  • Next-level constructs: fusion or assembly of multiple organoids representing different brain regions (76:35).
  • Enable the study of cell migration, synapse formation, and multi-region circuit activity.
  • The goal: recapitulate disease biology, identify druggable targets, and eventually test interventions on living human circuits.

5. Modeling Disease and Developing Drugs Using Human "Brain in a Dish"

• Timothy Syndrome Example:
  • Patient skin biopsies → iPSC → neurons in a dish → circuit dysfunctions seen and studied (62:32).
  • Drug development: labs can screen for compounds that reverse neuronal or circuit deficits in patient-derived assembloids.
  • "Every single defect that we've described...can be rescued by just adding the tiny piece of nucleic acid. It's almost like a gene therapy." — Dr. Pașca (124:16)
• Beyond Autism:
  • Applying assembloid technology to model epilepsy, schizophrenia (esp. 22q11 deletion), intellectual disability, pain syndromes, and (Dr. Huberman’s request) dystonia (129:22).

6. Translational and Experimental Frontiers

Gene Therapy & CRISPR (34:05)

• CRISPR technology allows precise repair of genetic mutations; has already been used for blood diseases.
• For brain disorders, challenges remain: large genes may not fit into viral vectors; targeting the right cell population; safety (immune system, off-target effects).
• Timing is crucial: In the adult brain, integration of new cells or circuits is much more limited than during development (106:53).

Transplantation & Human–Animal Chimeras

• Transplanting human brain organoids into animals: early transplantation allows human cells to integrate and mature, but only partial and species-limited integration (113:08).
• Allows testing of drug response and disease progression in "in vivo" context.

7. Ethical & Social Issues

Core concerns:

• Consent and the provenance of human cells.
• Potential for emergent properties (learning, sentience?).
• Language matters: not "mini-brains," but "organoids," "assembloids," etc. to avoid sensationalism and misrepresentation.
• "What really matters a lot...is the timing when you actually transplant those cells... The brain, [in] the adult, is not very permissive to forming new connections." — Dr. Pașca (106:53)
• Dr. Pașca leads collaborative efforts on nomenclature and ethical guidelines (97:16; 102:50).

Genetic Screening & Selection

• Growing capacity for genetic diagnosis raises questions about eugenics, reproductive choices, and variable penetrance.
• "For some of these conditions, it's more straightforward than for others... but the penetrance is variable..." — Dr. Pașca (119:05)

8. Science Communication, Nomenclature & Collaboration

• The need for specificity and restraint in language, both inside and outside the scientific community (102:01).
• "[Use] terms that are not trivializing... There are always ways of explaining science very simply, but also communicating that science changes over time, that there are new understandings that are correcting the science." — Dr. Pașca (104:19)
• Extensive consortium efforts foster standardization and responsible progress in stem cell–based neuroscience (102:50).

9. The Human Motivation and Vision

• Dr. Pașca’s work ethic and motivations: stemming from direct clinical experience with severe psychiatric disorders and driven by the transformative potential of these new technologies (135:03).
• Emphasis on compassion, hope, and the need to focus on the most debilitating, “profound” forms of disease for maximum real-world impact (132:29).

Notable Quotes & Memorable Moments

On the Mystery of Autism's Prevalence:

"Certainly the increase is still puzzling... The definition of the condition is quite difficult... that's the challenge with psychiatric disorders. The power of modern medicine is in molecular biology... but you need to have a very clear definition of what that disease is." — Dr. Pașca (22:23)

On Organoid Self-Organization:

"What we started actually to realize was that... biology was based on chemical and physical factors... but we've never truly leveraged this next level... which is self-organization. The ability of a biological system to build itself." — Dr. Pașca (78:59)

Naming Assembloids:

"He [Ben Barris] kept insisting that I should find the name... I thought, 'organoid' because it's organ-like... and then 'assemble' because we assemble the circuits... I sent this [name] and it says, 'Perfect, I love it.'" — Dr. Pașca (77:10)

On Scientific Progress:

"Science is getting more complex, biology is getting really, really complex, and there's no one single lab that can solve all of that." — Dr. Pașca (102:50)

On the Importance of Language:

"[Scientists are] told, try to simplify so that the public understand, the public understands much more than we think... always ways you can explain something without trivializing it." — Dr. Pașca (104:19)

On the Hope of Patient-derived Therapies:

"This will be the first therapeutic for psychiatric disease that has been exclusively developed with human stem cell models without anything else." — Dr. Pașca (124:25)

On Nomenclature and Ethics:

"We never say that an organoid sees just because there's a retina. We'll never say that a cortical organoid has intelligence because that's a property of an entire nervous system." — Dr. Pașca (97:58)

Important Timestamps

| Time | Topic/Quote | |-----------|---------------------------------------------------------------------| | 03:03 | Autism as a spectrum; behavioral diagnosis | | 04:37 | Twin studies & heritability of autism | | 07:31 | Autism sex ratios, diagnostic differences in males/females | | 15:18 | Microbiome and other failed autism hypotheses | | 17:38 | Genetic categories: channelopathies, synaptopathies, chromatinopathies| | 19:22 | Only 20% of autism patients receive a specific genetic diagnosis | | 24:08 | Environmental factors and genetics in autism | | 34:05 | Gene therapy and CRISPR – technical challenges | | 45:04 | Ethical debate on embryonic stem cells and Yamanaka breakthrough | | 60:32 | Building and maturing organoids | | 70:18 | Organoids recapitulating developmental timing, intrinsic clocks | | 76:35 | Introduction of the term "assembloid" | | 97:16 | Ethical concerns and Dr. Pașca’s field-wide standardization efforts | | 113:08 | Human organoid transplantation—timing and integration | | 124:24 | Timothy Syndrome as an example of stem cell–based therapy | | 129:22 | Challenges and requests for research in underrepresented disorders, like dystonia| | 135:03 | Dr. Pașca’s motivation and personal work ethic |

In-Depth Segments & Quotes

Autism "Not One Thing":

"Another way of thinking about autism is that autism is not one disease...think about fever of the 19th century... the treatments [for the underlying causes] are very different... In autism ...they are defined behaviorally, but there is a disconnect with the biology." — Dr. Pașca (06:24)

Stem Cell Ethical Breakthrough:

"Shinya Yamanaka...came up with an absolutely brilliant idea...suddenly you could take a skin cell from anybody...turn those cells into pluripotent stem cells that we'd later on learn they're almost identical to those embryonic stem cells." — Dr. Pașca (46:00–47:34)

Patient-driven Therapy:

"All we need to do is generate this tiny piece of nucleic acid that... switch the way the channel is processed and rescue or reverse the phenotypes." — Dr. Pașca (124:24)

On Language and Public Trust:

"We think that this is actually quite important, especially in communicating with the public. And that consortium turned out to be an actually great exercise of getting everybody together and now thinking, what are some of the common practices that we should all use when we report this experiment?" — Dr. Pașca (102:50)

Reflection on Scientific Discovery and Progress:

"I think it's so fun to think about the human brain. It's certainly fascinating to think about the biology of these conditions. For me, training as a physician, I think seeing firsthand some of the devastating effects of psychiatric disorders was a very strong motivation." — Dr. Pașca (135:50)

Final Thoughts

The episode is a tour de force through the genetics, biology, and latest models of complex brain disease, rooted in rigorous science and deep compassion. Dr. Pașca, with Dr. Huberman, illuminates a thrilling—and hopeful—future where patient cells can reveal mechanisms and drive new treatments, when responsible language and ethics are embedded in scientific advance, and where collaboration, not competition, is the norm.

Dr. Huberman concludes:

"I'm absolutely convinced this is the way science is going to be done on the brain to cure neurologic and psychiatric diseases... Whatever we have to do to keep you going... this is super exciting." (137:41)

Recommended for anyone interested in:

• Autism and neurodevelopmental/psychiatric diseases
• Genetics and new frontiers in neuroscience research
• Translational and ethical challenges in modern biomedicine
• Living, breathing stories of scientific discovery and hope

For further reading and resources, see the episode show notes and links provided by the Huberman Lab podcast.